Multiplex High-Throughput Cytokine Release Syndrome (CRS) Biomarker Detection Service

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Contact

Current challenges in CRS management include the lack of early, predictive biomarkers, the extreme heterogeneity of patient cytokine responses, and the inability of conventional single-plex assays to capture the rapid, polyclonal dynamics of immune activation after CAR-T cell therapy. To address these gaps, we offer our Multiplex High-Throughput CRS Biomarker Detection Service — a comprehensive platform designed for simultaneous, quantitative profiling of multiple key cytokines and chemokines from a single, small-volume sample. Our service integrates automated liquid-handling systems with advanced multiplex arrays, delivering high-sensitivity, reproducible data with rapid turnaround. This empowers your research and clinical development teams with early risk stratification, real-time immune monitoring, and actionable insights to guide intervention strategies.

Introduction

Cytokine release syndrome (CRS) remains the most prominent acute toxicity associated with CAR‑T cell therapies, driven by exponential immune activation following target engagement. A spectrum of soluble biomarkers, including interferon‑gamma, interleukin‑6, and tumor necrosis factor‑alpha, has been established to reflect the severity and trajectory of the hyperinflammatory response. Precise, longitudinal monitoring of these mediators is therefore critical for early risk stratification, timely intervention, and improved patient outcomes across immuno‑oncology protocols.

Fig.1 CRS emerges as a consequence of CAR-T cell therapy. (OA Literature) Fig.1 CRS occurs after CAR-T cell treatment.¹

Our Service

Our Multiplex High-Throughput CRS Biomarker Detection Service quantifies critical immune regulators simultaneously from minimal sample volumes. Designed for preclinical and clinical workflows, this advanced platform mitigates matrix interference and cross-reactivity to deliver ultra-sensitive, robust data. We empower drug developers with accelerated timelines, precise risk assessment, and actionable insights to safeguard novel immunotherapies.

What We Can Offer

We offer a comprehensive, high-throughput biomarker detection platform that combines cutting-edge multiplex arrays, ultra-sensitive detection, and automated microfluidics to deliver rapid, precise, and highly specific cytokine profiling for early-stage CRS monitoring and immunotherapy development.

Featured services of multiplex high-throughput CRS biomarker detection service at Creative Biolabs. (Creative Biolabs Original)

Our Service Process

Required Starting Materials:

Serum or Plasma.
Cell Culture Supernatants.
Tissue Homogenates.

Key Steps:

Workflow of multiplex high-throughput CRS biomarker detection service at Creative Biolabs. (Creative Biolabs Original)

Final Deliverables:

Raw and Analyzed Data.
Statistical and Visual Graphics.

Key Advantages

Comprehensive Immune Profiling: By capturing the dynamic balance between pro-inflammatory and anti-inflammatory cytokines, this service delivers a holistic mapping of immune responses without missing critical secondary biomarkers.
Ultra-Wide Dynamic Range: Our service accommodates massive concentration spikes typical of CRS, precisely quantifying both ultra-high and baseline biomarker levels simultaneously without the need for tedious serial dilutions.
Minimal Sample Volume Requirement: Optimized to require only a minimal amount of serum, plasma, or supernatant, this service preserves precious, hard-to-acquire clinical or small-animal samples while enabling frequent longitudinal monitoring.

FAQ

Q1: What measures are implemented to mitigate antibody cross-reactivity in multiplex assays?

A1: During the assay development phase, panels undergo rigorous specificity validation. Should severe interference occur between specific analytes, they are segregated into distinct panels to ensure data integrity.

Q2: Can this service accommodate diverse sample matrices?

A2: Yes. To account for varying biological matrices, ranging from in vitro whole blood stimulation and PBMC culture supernatants to in vivo humanized mouse or non-human primate (NHP) sera, matrix-specific diluents are deployed to neutralize matrix effects and guarantee precise quantification.

Why Choose Us?

Our platform delivers multiplex, high‑throughput CRS biomarker profiling with exceptional sensitivity and broad dynamic range. Leveraging validated antibody arrays and automated workflows, we ensure reproducible, quantitative data from minimal sample volumes. Accelerate your immunotherapy safety assessment with rapid turnaround, expert support, and rigorous quality control tailored to your translational research needs.

Customer Reviews

" During the lead optimization of our next-generation CAR-T pipeline, predicting Cytokine Release Syndrome (CRS) was our highest hurdle. This multiplex high-throughput detection service allowed us to screen over 40 cytokines simultaneously from tiny volumes of co-culture supernatants. The sensitivity of the assay helped us identify subtle triggers for IL-6 and IFN-gamma release that traditional ELISAs missed. " Dr. A* E*.

"For T cell engaging bispecific antibodies, CRS is a major clinical risk. We used this high-throughput service to profile cytokine release patterns across a massive panel of donor PBMC assays. The platform's ability to process 384-well plates with exceptional reproducibility and a rapid turnaround time was outstanding. The multiplex data allowed us to rank our candidates based on a safer therapeutic window." Dr. M* C*.

How to contact us?

Interested in progressing your CRS biomarker investigations? Our specialists are on hand to advise on bespoke panel configurations, specimen needs, and study scheduling. To receive a rapid cost estimate or engage in a technical dialogue, kindly submit our web form or forward your queries to our assistance team. We guarantee a tailored, expert response aligned with your project objectives.

Reference

Tvedt, Tor Henrik Anderson et al. "Cytokine Release Syndrome in the Immunotherapy of Hematological Malignancies: The Biology behind and Possible Clinical Consequences." Journal of clinical medicine vol. 10,21 5190. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3390/jcm10215190.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.